Efficacy of glucosamine alendronate alone & in combination with dihydroquercetin for treatment of osteoporosis in animal model

Indian Journal of Medical Research

Volumn 135, Issue 2, 2012, Pages 221-227

  Muraleva, Natalya A ^a,b   Ofitserov, Evgeniy N ^c   Tikhonov, Vladimir P ^d   Kolosova, Natalya G ^a  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b NOVOSIBIRSK RESEARCH INSTITUTE OF TRAUMATOLOGY AND ORTHOPAEDICS N A YA L TSIVYAN   (Russian Federation)

^c MENDELEEV UNIVERSITY OF CHEMICAL TECHNOLOGY OF RUSSIA   (Russian Federation)

^d Diode Plant   (Russian Federation)

Author keywords

Alendronate; Glucosamine; Osteoporosis; OXYS rats; Strength of bone

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; GLUCOSAMINE ALENDRONATE; OSTEOCALCIN; TAXIFOLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITOMETRY; BONE STRENGTH; CALCIUM BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMUR; MALE; MONOTHERAPY; NONHUMAN; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RAT; SENESCENCE;

ALENDRONATE; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; COLLAGEN TYPE I; DRUG SYNERGISM; GLUCOSAMINE; HUMANS; MALE; OSTEOCALCIN; OSTEOPOROSIS; QUERCETIN; RATS; RATS, WISTAR;

EID: 84859030495     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Castillo H, Samson-Fang L. American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 2009; 51: 17-29.
2. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-59.
3. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J Feb 2008; 49: 119-28.
4. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. Yonsei Med J Aug 2009; 50: 474-81.
5. Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, et al. Alendronate reduces adhesion of human osteoclast- like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998; 63: 230-5.
6. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-105.
7. D'Amelio P, Grimaldi A, Isaia GC. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int 2010; 21: 1741-50.
8. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev Jan 2008; (1):CD001155.
9. Sasaki H, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Kamo K, et al. Effects of combination treatment with alendronate and vitamin K(2) on bone mineral density and strength in ovariectomized mice. J Bone Miner Metab 2010; 28: 403-9.
10. Ringe JD. Combination treatment in osteoporosis. Basic treatment plus specific osteoporosis medication. Med Monatsschr Pharm 2009; 32: 137-40.
11. Vladimirov YA, Proskurnina EV, Demin EM, Matveeva NS, Lubitskiy OB, Novikov AA, et al. Dihydroquercetin (taxifolin) and other flavonoids as inhibitors of free radical formation at key stages of apoptosis. Biochemistry (Mosc) 2009; 74: 301-7.
12. Tarahovsky YS, Selezneva II, Vasilieva NA, Egorochkin MA, Kim YA. Acceleration of fibril formation and thermal stabilization of collagen fibrils in the presence of taxifolin (dihydroquercetin). Bull Exp Biol Med 2007; 144: 791-4.
13. Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA. et al. The laboratory rat as an animal model for osteoporosis research. Comp Med 2008; 58: 424-30.
14. Takeda T, Hosokawa M, Higuchi K. Senescence-accelerated mouse (SAM): a novel murine model of senescence. Exp Gerontol 1997; 32: 105-9.
15. Chen H, Zhou X, Emura S, Shoumura S. Site-specific bone loss in senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis. Exp Gerontol 2009; 44: 792-8.
16. Kolosova NG, Kutorgin GD, Safina AF. Bone mineralization in senescence-accelerated OXYS rats. Bull Exp Biol Med 2002; 133: 171-4.
17. ,s elemental composition determination. Nucl Instr Meth Phys Res A 2005; 543: 271-3.
18. Falameeva OV, Sadovoi OV, Khrapova YuV Kolosova NG. (2006) Structural and functional changes in bone tissue of the spine and limbs in rats OXYS. Khirurgiya Pozvonochnika 2006; 1: 88-94.
19. Muraleva NA, Sadovoi MA, Kolosova NA. Features of development osteoporosis in accelerated senescent OXYS rats. Adv Gerontol 2010; 23: 233-43.
20. Adami S, Prizzi R, Colapietro F. Alendronate for the treatment of osteoporosis in men. Calcif Tissue Int 2001; 69: 239-41.
21. Lopes R, Coeli CM, Vaisman M, de Farias MLF. Additional beneficial effects of recombinant growth hormone in alendronate-treated patients with idiopathic osteoporosis. Endocrine Journal 2009; 56: 851-8.
22. Olszynski WP, Davison KS, Ioannidis G. Brown JP, Hanley DA, Josse RG, et al. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. Osteoporos Int 2006; 17: 217-41.
23. Abbaspour A, Takahashi M, Sairyo K, Takata S, Yukata K, Inui A, et al. Optimal increase in bone mass by continuous local infusion of alendronate during distraction osteogenesis in rabbits. Bone 2009; 44: 917-23.
24. Zhao J, JiangY, Genant HK. Preclinical studies of alendronate. J Muscul Res 1991; 3: 209-16.
25. Leeming DJ, Henriksen K, Byrjalsen I, Qvist P, Madsen SH, Garnero P, et al. Is bone quality associated with collagen age? Osteoporos Int 2009; 20: 1461-70.
26. Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int 2006; 17: 319-36.
27. Chen Y, Deuster P. Comparison of quercetin and dihydroquercetin: antioxidant-independent actions on erythrocyte and platelet membrane. Chem Biol Interact 2009; 182: 7-12.
28. Wattel A, Kamel S, Mentaverri R, Lorget F, Prouillet C, Petit JP, et al. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol 2003; 65: 35-42.
29. Wattel A, Kamel S, Prouillet C, Petit JP, Lorget F, Offord E, et al. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J Cell Biochem 2004; 92: 285-95.
30. Woo JT, Nakagawa H, Notoya M, Yonezawa T, Udagawa N, Lee IS, Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol Pharm Bull 2004; 27: 504-9.
31. Trivedi R, Kumar S, Kumar A, Siddiqui JA, Swarnkar G, Gupta V, et al. Kaempferol has osteogenic effect in ovariectomized adult Sprague-Dawley rats. Mol Cell Endocrinol 2008; 289: 85-91.